Cargando…

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Detalles Bibliográficos
Autores principales:	van Kempen, Zoé LE, Rispens, Theo, Killestein, Joep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971362/ https://www.ncbi.nlm.nih.gov/pubmed/28990853 http://dx.doi.org/10.1177/1352458517734073

Ejemplares similares

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Pulmonary eosinophilia associated to treatment with natalizumab
por: Curto, Elena, et al.
Publicado: (2016)

Identification of Peptide Mimotope Ligands for Natalizumab
por: Ruff, Laura E., et al.
Publicado: (2018)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l333oqp5uidq03vdgr7o5jnfvu